ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2013
10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 270 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
270 citing papers in PubMed, 1 synthesis or guideline pooled it, 693 citations in OpenAlex.
- A combination of photodynamic therapy and antimicrobial compounds to treat skin and mucosal infections: a systematic review.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2019Pooled it
- Randomized Noninferiority Trial of Cefoperazone-Sulbactam versus Cefepime in the Treatment of Hospital-Acquired and Healthcare-Associated Pneumonia.Antimicrobial agents and chemotherapy · 2019Trial
- Impact of Real-Time Therapeutic Drug Monitoring on the Prescription of Antibiotics in Burn Patients Requiring Admission to the Intensive Care Unit.Antimicrobial agents and chemotherapy · 2018Trial
- Cost Drivers of a Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Phase 3 Clinical Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018Trial
- A New Simplified Coralmycin Derivative with Potent Anti-Gram-Negative Activity and Its Congeners Produced by the MyxobacteriumJournal of microbiology and biotechnology · 2026Article
- Article
- Medicinal Plants: A Promising Therapeutic Approach for Addressing Antimicrobial Resistance.International journal of molecular sciences · 2026Review
- Mapping the Proteomes of Bacteriophages E215 and LUZ19 Using Liquid Chromatography Tandem Mass Spectrometry.Advances in experimental medicine and biology · 2026Article
- Contact precautions prevent cross-contamination of extended-spectrum beta-lactamase-producing Enterobacterales in an intensive care unit: a prospective observational study.Annals of intensive care · 2025Article
- Protein-Protein Interactions as Promising Molecular Targets for Novel Antimicrobials Aimed at Gram-Negative Bacteria.International journal of molecular sciences · 2025Review
- Evaluation of the Activity of Amino Chalcone AgainstPharmaceuticals (Basel, Switzerland) · 2025Article
- Review
- Article
- Development of Broad-Spectrum Antimicrobial Peptides through the Conjugation of FtsZ-Binding and Cell-Penetrating Peptides.ACS infectious diseases · 2025Article
- Antimicrobial Multidrug Resistance and Mechanisms of Action: An Overview.BioMed research international · 2025Review
- Pd-, Cu-, and Ni-Catalyzed Reactions: A Comprehensive Review of the Efficient Approaches towards the Synthesis of Antibacterial Molecules.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Zinc Oxide-Based Nanomaterials for Microbiostatic Activities: A Review.Journal of functional biomaterials · 2024Review
- Antibacterial and sunlight-driven photocatalytic activity of graphene oxide conjugated CeOScientific reports · 2024Article
- Meropenem-ANT3310, a unique β-lactam-β-lactamase inhibitor combination with expanded antibacterial spectrum against Gram-negative pathogens including carbapenem-resistantAntimicrobial agents and chemotherapy · 2024Article
- Treatment of MRSA Infection: Where are We?Current medicinal chemistry · 2024Review
210 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 1 country.
Funding
Abstract
Infections caused by antibiotic-resistant bacteria, especially the "ESKAPE" pathogens, continue to increase in frequency and cause significant morbidity and mortality. New antimicrobial agents are greatly needed to treat infections caused by gram-negative bacilli (GNB) resistant to currently available agents. The Infectious Diseases Society of America (IDSA) continues to propose legislative, regulatory, and funding solutions to this continuing crisis. The current report updates the status of development and approval of systemic antibiotics in the United States as of early 2013. Only 2 new antibiotics have been approved since IDSA's 2009 pipeline status report, and the number of new antibiotics annually approved for marketing in the United States continues to decline. We identified 7 drugs in clinical development for treatment of infections caused by resistant GNB. None of these agents was included in our 2009 list of antibacterial compounds in phase 2 or later development, but unfortunately none addresses the entire spectrum of clinically relevant GNB resistance. Our survey demonstrates some progress in development of new antibacterial drugs that target infections caused by resistant GNB, but progress remains alarmingly elusive. IDSA stresses our conviction that the antibiotic pipeline problem can be solved by the collaboration of global leaders to develop creative incentives that will stimulate new antibacterial research and development. Our aim is the creation of a sustainable global antibacterial drug research and development enterprise with the power in the short term to develop 10 new, safe, and efficacious systemically administered antibiotics by 2020 as called for in IDSA's "10 × '20 Initiative."
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.